Migdal Insurance & Financial Holdings Ltd. reduced its stake in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 45.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 370,000 shares of the company’s stock after selling 306,000 shares during the quarter. Migdal Insurance & Financial Holdings Ltd.’s holdings in AstraZeneca were worth $59,744,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AZN. Professional Advisory Services Inc. bought a new stake in shares of AstraZeneca in the 2nd quarter worth about $30,241,000. Wealthcare Advisory Partners LLC purchased a new position in shares of AstraZeneca during the 2nd quarter worth about $2,296,000. Andra AP fonden grew its holdings in AstraZeneca by 122.9% during the 2nd quarter. Andra AP fonden now owns 526,714 shares of the company’s stock valued at $99,876,000 after purchasing an additional 290,412 shares during the last quarter. International Assets Investment Management LLC grew its holdings in AstraZeneca by 1,564.8% during the 3rd quarter. International Assets Investment Management LLC now owns 28,785 shares of the company’s stock valued at $4,648,000 after purchasing an additional 27,056 shares during the last quarter. Finally, Westport Asset Management Inc. bought a new position in AstraZeneca during the 2nd quarter valued at about $1,422,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of analysts recently weighed in on the stock. Zacks Research raised shares of AstraZeneca from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 13th. Citigroup restated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, October 6th. Royal Bank Of Canada began coverage on AstraZeneca in a research note on Tuesday, September 8th. They set an “outperform” rating on the stock. Nordea Equity Research upgraded AstraZeneca from a “sell” rating to a “buy” rating in a report on Tuesday, October 13th. Finally, CICC Research assumed coverage on AstraZeneca in a report on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 price target on the stock. Sixteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, AstraZeneca currently has a consensus rating of “Moderate Buy” and an average price target of $206.67.
Get Our Latest Stock Analysis on AZN
AstraZeneca Trading Up 0.2%
Shares of NYSE AZN traded up $0.28 during mid-day trading on Friday, reaching $184.66. The company had a trading volume of 1,849,945 shares, compared to its average volume of 3,101,796. The stock has a market cap of $286.40 billion, a price-to-earnings ratio of 26.12, a price-to-earnings-growth ratio of 1.43 and a beta of 0.24. AstraZeneca Plc has a 52 week low of $153.41 and a 52 week high of $212.71. The business’s 50-day moving average is $168.82 and its 200-day moving average is $180.20. The company has a current ratio of 1.01, a quick ratio of 0.79 and a debt-to-equity ratio of 0.51.
AstraZeneca (NYSE:AZN – Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The company reported $2.79 earnings per share for the quarter, beating analysts’ consensus estimates of $2.60 by $0.19. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The company had revenue of $16.21 billion during the quarter, compared to analyst estimates of $16 billion. During the same quarter last year, the business posted $2.38 EPS. The firm’s revenue for the quarter was up 6.5% on a year-over-year basis. Equities analysts expect that AstraZeneca Plc will post 10.22 earnings per share for the current year.
AstraZeneca Company Profile
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
See Also
- Five stocks we like better than AstraZeneca
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
